BIIB-023

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameBIIB-023
Drug Alias NameBIIB-023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor ligand superfamily member 12 inhibitors
TargetsTumor necrosis factor ligand superfamily member 12
Therapy Area/IndicationsLupus NephritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsLupus NephritisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A